Salt and TH-17 in Healthy Human Subjects
NCT02261688 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9
Last updated 2021-06-08
Summary
The overall goal of this study is to evaluate the association between sodium and TH17 cells in human subjects. The subjects will have levels of TH-17 and various hormones measured on low salt diet, low salt diet with intravenous normal saline, and high salt diet.
Conditions
- Th17 Helper Immune Cells
- Autoimmunity
- Salt Intake
- Sodium Chloride
Interventions
- DIETARY_SUPPLEMENT
-
Low salt diet
Low salt diet, 10mmoL of sodium per day, for 6 days
- DIETARY_SUPPLEMENT
-
Low salt diet + IV normal saline
Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
- DIETARY_SUPPLEMENT
-
Liberal salt diet
Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
Sponsors & Collaborators
-
Brigham and Women's Hospital
lead OTHER
Principal Investigators
-
Gordon Williams, MD · Brigham and Women's Hospital
Study Design
- Allocation
- NA
- Purpose
- BASIC_SCIENCE
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 45 Years
- Sex
- MALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2014-03-31
- Primary Completion
- 2019-07-31
- Completion
- 2019-08-31
Countries
- United States
Study Locations
More Related Trials
-
Study of Immune Globulin Intravenous (Human) GC5101F in Subjects With Primary Humoral Immunodeficiency
NCT03492710 ·Status: WITHDRAWN ·Phase: PHASE3
-
COVID-19 Vaccine Responses in PIDD Subjects
NCT05321407 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections
NCT00417573 ·Status: COMPLETED ·Phase: PHASE2
-
Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE)
NCT00839436 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD
NCT01485796 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults
NCT01274429 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort)
NCT04927169 ·Status: TERMINATED ·Phase: PHASE2
-
Antibody Production in Immune Disorders
NCT00023504 ·Status: TERMINATED ·Phase: PHASE4
-
A Single-arm, Dose-escalation Trial of Long-acting Recombinant Human IL-7 (NT-I7, Efineptakin Alfa) for Idiopathic CD4 Lymphopenia
NCT05600920 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Effect of Xolair (Omalizumab) on Allergy Blood Cells
NCT00657891 ·Status: COMPLETED ·Phase: PHASE4
-
Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects
NCT00546871 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Hemophagocytic Lymphohistiocytosis (HLH) Evaluation and Research of Clinical, ImmUnoLogic and TranscriptomE Study
NCT06339177 ·Status: RECRUITING
-
Phase 2/3 Study of IGSC, 20% in PIDD
NCT01218438 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Role of Circulating Innate Lymphoid Cells in Allergic Disorders
NCT03069495 ·Status: TERMINATED
-
A Study of LY3006072 in Healthy Participants
NCT01640249 ·Status: TERMINATED ·Phase: PHASE1
-
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH)
NCT02007239 ·Status: WITHDRAWN ·Phase: PHASE2
-
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
NCT07190196 ·Status: RECRUITING ·Phase: PHASE3
-
A Study to Determine the Immunogenicity and Oral Tolerance to Keyhole Limpet Hemocyanin (KLH)
NCT01489956 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Use of Immune Globulin Plus Rituximab for Desensitization in Highly HLA Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
NCT01178216 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Interleukin-1 Trap to Treat Autoinflammatory Diseases
NCT00094900 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of Abatacept in IgG4-Related Disease
NCT03669861 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab Trial for Pediatric Nephrotic Syndrome
NCT01716442 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)
NCT01066598 ·Status: TERMINATED ·Phase: PHASE2
-
Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID
NCT01175213 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
NCT07222553 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2